Multidisciplinary mHealth Rehabilitation for Patients With Abdominal Cancer Who Are Receiving Chemoradiotherapy: Randomized Phase II Trial
Journal of Medical Internet Research · 08.09.2026 · 28 · e98330-e98330
DOI: 10.2196/98330 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Medical Internet Research, online erschienen am 08.09.2026. Verfasst von Lei Yang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Ho…. Hauptthemen laut MEDLINE: Chemoradiotherapy, Telemedicine. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Concurrent chemoradiotherapy (CCRT) for abdominal cancer frequently induces muscle loss, weight loss, and malnutrition.
Objective
This exploratory randomized phase II trial evaluated whether a multidisciplinary, mobile health (mHealth)–based multimodal rehabilitation program could preserve handgrip strength and muscle mass in patients with abdominal cancer undergoing CCRT.
Methods
In this prospective, multicenter, randomized, open-label phase II trial (NCT05325554), 111 eligible patients with abdominal malignancies scheduled for CCRT were randomly assigned (1:1) to receive either multidisciplinary mHealth rehabilitation care (MRC; n=57) or standard care (SC; n=54). The MRC program was delivered by a dedicated multidisciplinary team using the AiNST mHealth platform and wearable heart rate monitors. The primary end point was handgrip strength at the end of CCRT (analyzed with analysis of covariance adjusting for baseline). Secondary end points were exploratory and analyzed without multiplicity adjustment; sensitivity analysis using false discovery rate (FDR) correction was performed.
Results
Between February 2022 and April 2023, 111 patients were enrolled. Adherence was high (n=93, 83.9% achieved exercise targets). After adjusting for baseline handgrip strength, the MRC group had significantly higher handgrip strength at the end of CCRT than the SC group (adjusted mean difference 4.87 kg, 95% CI 3.36‐6.38; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, and Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, China, 86…
- Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, Hubei, China.
- Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
- Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
- Wuhan Sports University, Wuhan, Hubei, China.
- Beijing Ainst Medical Technology Co., Ltd, Beijing, China.
Zitieren
APA
Yang, L., Wang, W., Su, J., Xiong, Y., Wu, H., Wang, Y., Dai, J., Cao, D., Peng, J., Xia, L., Jiang, H., Xu, H., Wang, Q., Chen, F., Shu, Q., Hao, C., Lv, K., Shang, W., Xu, H., …, & Zhou, F. (2026). Multidisciplinary mHealth Rehabilitation for Patients With Abdominal Cancer Who Are Receiving Chemoradiotherapy: Randomized Phase II Trial. Journal of Medical Internet Research, 28, e98330-e98330. https://doi.org/10.2196/98330
Vancouver
Yang L, Wang W, Su J, Xiong Y, Wu H, Wang Y, et al. Multidisciplinary mHealth Rehabilitation for Patients With Abdominal Cancer Who Are Receiving Chemoradiotherapy: Randomized Phase II Trial. Journal of Medical Internet Research. 2026;28:e98330-e98330. doi:10.2196/98330
BibTeX
@article{Yang2026,
author = {Yang, Lei and Wang, Wenbo and Su, Jing and Xiong, Yudi and Wu, Han and Wang, You and Dai, Jing and Cao, Dedong and Peng, Jin and Xia, Ling and Jiang, Huangang and Xu, Hui and Wang, Qingyun and Chen, Fengxia and Shu, Qing and Hao, Chizi and Lv, Ke and Shang, Weihu and Xu, Honghong and Zhang, Ying and Chen, Weidong and Xu, Ximing and Shi, Hanping and Zhou, Fuxiang},
title = {Multidisciplinary mHealth Rehabilitation for Patients With Abdominal Cancer Who Are Receiving Chemoradiotherapy: Randomized Phase II Trial},
journal = {Journal of Medical Internet Research},
year = {2026},
volume = {28},
pages = {e98330--e98330},
doi = {10.2196/98330}
}
EUVIMED